紫云英苷对未分化胃癌细胞凋亡的影响 *

doi:10.12047/j.cjap.6259.2022.097

中国应用生理学杂志 ›› 2022, Vol. 38 ›› Issue (5): 520-524.doi: 10.12047/j.cjap.6259.2022.097

紫云英苷对未分化胃癌细胞凋亡的影响 ^*

褚智恒⁺, 何施燕⁺, 王瑜, 朱若婷, 顾益玲, 陈佳玉^△

绍兴文理学院医学院, 浙江绍兴 312000

收稿日期:2022-01-20 修回日期:2022-09-28 出版日期:2022-09-28 发布日期:2023-04-23
通讯作者: ^△Tel: 0575-88345826; E-mail: chenyujia10@163.com
作者简介:⁺: 为共同第一作者
基金资助:
^*国家级大学生创新创业训练计划项目(202010349038)

Effects of Astragalin on apoptosis of undifferentiated gastric cancer cells

CHU Zhi-heng⁺, HE Shi-yan⁺, WANG Yu, ZHU Ruo-ting, GU Yi-ling, CHEN Jia-yu^△

Shaoxing University School of Medicine, Shaoxing 312000, China

Received:2022-01-20 Revised:2022-09-28 Online:2022-09-28 Published:2023-04-23

摘要/Abstract

摘要： 目的: 探讨紫云英苷(Astragalin)对未分化胃癌细胞HGC-27的作用及相关分子机制。方法: 将紫云英苷作用HGC-27细胞,设置对照组(0 μg/ml)和Astragalin组(12.5、25、50 μg/ml),每组设置3复孔,用CCK-8法分别在用药0、24、48、72 h后检测细胞增殖活性; 在浓度为0、50 μg/ml的Astragalin作用24 h后,倒置显微镜下观察细胞形态,hoechst 33342、JC-1染色观察其核形和线粒体膜电位,流式细胞仪检测细胞周期和凋亡率的改变,二代测序仪分析基因的逆转录水平。结果: 紫云英苷可明显抑制HGC-27的增殖(P＜0.01),下调细胞线粒体膜电位,诱导细胞凋亡,使细胞周期阻滞于G1期(P＜0.01)。同时,紫云英苷上调基因bax、bad的转录水平,抑制egf、egfr、pik3cb、pdk1、akt3、bcl-2和sgk3基因的转录(P＜0.01)。Western blot实验也证实紫云英苷降低PI3K和AKT蛋白的表达,同时BAX和BCL-2蛋白的比例也显著增加(P＜0.01)。结论: 紫云英苷可通过抑制EGFR/PDK/AKT信号通路诱导未分化型胃癌细胞HGC-27凋亡,并将细胞周期阻滞于G1期,对未分化胃癌具有一定的治疗作用。

关键词: 紫云英苷, 胃癌, 信号通路, 细胞凋亡, 细胞培养

Abstract: Objective: To investigate the effects and related molecular mechanisms of Astragalin on undifferentiated gastric cancer cell HGC-27. Methods: Astragalin was used to treat HGC-27 cells, the cell proliferation activity was detected by CCK-8 method, the cell morphology was observed under inverted microscope, hoechst 33342 and JC-1 staining were used to observe the changes of nucleus formation and mitochondrial membrane potential, the cell cycle and apoptosis rate were detected by flow cytometry, the reverse transcription level of the gene was analyzed by the second-generation sequencer. Results: Astragalin inhibited the proliferation of HGC-27 significantly (P＜0.01), down-regulated mitochondrial membrane potential, induced cell apoptosis, blocked the cell cycle in G1 prophase. At the same time, Astragalin up-regulated the transcription levels of genes bax and bad, down-regulated the transcription levels of genes egf, egfr, pik3cb, pdk1, akt3 and bcl-2. Western blot analysis also showed that the expressions of PI3K and Akt protein were decreased, and the proportion of Bax and BCL-2 protein was increased significantly (P＜0.01). Conclusion: The apoptosis of undifferentiated gastric cancer cell line HGC-27 can be induced by Astragalin through inhibition of EGFR/PDK/Akt signaling pathway, and the cell cycle can be blocked in G1 phase, which has a certain therapeutic effect on undifferentiated gastric cancer.

Key words: Astragalin, gastric cance, signaling pathway, cell apoptosis, cell culture

中图分类号:

R735.2

褚智恒, 何施燕, 王瑜, 朱若婷, 顾益玲, 陈佳玉. 紫云英苷对未分化胃癌细胞凋亡的影响 ^*[J]. 中国应用生理学杂志, 2022, 38(5): 520-524.

CHU Zhi-heng, HE Shi-yan, WANG Yu, ZHU Ruo-ting, GU Yi-ling, CHEN Jia-yu. Effects of Astragalin on apoptosis of undifferentiated gastric cancer cells[J]. CJAP, 2022, 38(5): 520-524.

参考文献

[1] Chung HC, Bang YJ, Fuchs CS, et al. First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811[J]. Future Oncol, 2021, 17(5): 491-501.
[2] 赵翔宇, 何振宇, 宰守峰. 人参皂苷Rg5对胃癌细胞周期和侵袭的影响及其机制[J]. 中国应用生理学杂志, 2020, 36(1) : 51-55.
[3] Ishigami H, Yamaguchi H, Yamashita H, et al. Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings[J]. Gastric Cancer, 2017, 20(1): 128-134.
[4] Kimura Y, Fujii M, Masuishi T, et al. Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06)[J]. Gastric Cancer, 2018, 21(3): 421-427.
[5] Liu L, Wang D, Qin Y, et al. Astragalin promotes osteoblastic differentiation in MC3T3-E1 cells and bone formation in vivo[J]. Front Endocrinol, 2019, 10: 228-238.
[6] Cid-Ortega S, Monroy-Rivera JA. Extraction of kaempferol and its glycosides using supercritical fluids from plant sources: A review[J]. Food Technol Biotech, 2018, 56(4): 480-493.
[7] Li W, Hao J, Zhang L, et al. Astragalin reduces hexokinase 2 through increasing miR-125b to inhibit the proliferation of hepatocellular carcinoma cells in vitro and in vivo[J]. J Agric Food Chem, 2017, 65(29): 5961-5972.
[8] Peng L, Gao X, Nie L, et al. Astragalin attenuates dextran sulfate sodium (DSS) -induced acute experimental colitis by alleviating gut microbiota dysbiosis and inhibiting NF-κB activation in mice[J]. Front Immunol, 2020, 11: 2058-2058.
[9] Guardiola S, Varese M, Sánchez-Navarro M, et al. A third shot at EGFR: New opportunities in cancer therapy[J]. Trends Pharmacol Sci, 2019, 40(12): 941-955.
[10] Lindner AU, Carberry S, Monsefi N, et al. Systems analysis of protein signatures predicting cetuximab responses in KRAS, NRAS, BRAF and PIK3CA wild-type patient-derived xenograft models of metastatic colorectal cancer[J]. Int J Cancer, 2020, 147 (10): 2891-2901.
[11] Lin JX, Xie XS, Weng XF, et al. UFM1 suppresses invasive activities of gastric cancer cells by attenuating the expression of PDK1 through PI3K/AKT signaling[J]. J Exp Clin Canc Res, 2019, 38(1): 410-425.
[12] Scortegagna M, Lau E, Zhang T, et al. PDK1 and SGK3 contribute to the growth of BRAF-mutant melanomas and are potential therapeutic targets[J]. Cancer Res, 2015, 75(7): 1399-1412.
[13] Chen L, Yang L, Yao L, et al. Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients[J]. Nat commun, 2018, 9(1): 1-17.
[14] Zhang L, Li Y, Wang Q, Chen Z, et al. The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer[J]. Mol Cancer, 2020, 19(1): 10-27.
[15] Yip PY. Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer[J]. Trans Lung Cancer Res, 2015, 4(2): 165-176.
[16] Wang X, Li G. MicroRNA-16 functions as a tumor-suppressor gene in oral squamous cell carcinoma by targeting AKT3 and BCL2L2[J]. J Cell Physiol, 2018, 233(12): 9447-9457.
[17] Glab JA, Cao Z, Puthalakath H. Bcl-2 family proteins, beyond the veil[J]. Int Rev Cel Mol Bio, 2020, 351: 1-22.
[18] Kalashnikova I, Mazar J, Neal CJ, et al. Nanoparticle delivery of curcumin induces cellular hypoxia and ROS-mediated apoptosis via modulation of Bcl-2/Bax in human neuroblastoma[J].Nanoscale, 2017, 9(29): 10375-10387.

紫云英苷对未分化胃癌细胞凋亡的影响 ^*

Effects of Astragalin on apoptosis of undifferentiated gastric cancer cells

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	钟锦, 史晋朝, 张倩, 孟金凤, 张倩倩, 李建国. Bdnf基因过表达慢病毒载体的构建及表达^*[J]. 中国应用生理学杂志, 2022, 38(5): 397-400.
[2]	陈丽, 陈金信, 王心怡, 李香兰, 姜海英. 组织蛋白酶K对大鼠空间学习记忆功能的影响^*[J]. 中国应用生理学杂志, 2022, 38(5): 412-417.
[3]	谢明仁, 何天晓, 袁霞, 张璟, 俞蕾, 俞发荣. 十八碳二烯酸对神经胶质瘤细胞增殖与凋亡的影响及其机制^*[J]. 中国应用生理学杂志, 2022, 38(5): 434-437.
[4]	陈津子, 李旭艳, 刘东梅, 龙舒婷, 李永媚, 陈泓冰. 纳米ZnO对人肺上皮细胞BEAS-2B细胞增殖和凋亡的影响^*[J]. 中国应用生理学杂志, 2022, 38(5): 443-447.
[5]	张紫媛, 方敬爱, 李苏芬, 胡雅玲, 刘文媛, 刘学军. 黄芪甲苷延缓肾脏衰老的作用及其机制^*[J]. 中国应用生理学杂志, 2022, 38(5): 448-452.
[6]	杜玥, 王志旺, 席建宏, 李济阳, 梁可克, 黄柯婷, 罗慧英. cAMP/Epac信号通路在当归治疗阴虚证慢性咳嗽中的作用^*[J]. 中国应用生理学杂志, 2022, 38(5): 475-479.
[7]	郭佳, 李志东, 肖传实, 边云飞. PUMA对高糖诱导的大鼠H9C2心肌细胞凋亡的作用及机制^*[J]. 中国应用生理学杂志, 2022, 38(5): 504-509.
[8]	严惠, 赵虎, 李论. 1-磷酸鞘氨醇(S1P)对H9c2心肌细胞肥大反应的保护作用^*[J]. 中国应用生理学杂志, 2022, 38(5): 510-514.
[9]	赵晓琴, 游佳琪, 刘晓然, 孙君志, 李俊平, 王瑞元. 大负荷运动诱导大鼠骨骼肌细胞凋亡的作用及线粒体凋亡机制^*[J]. 中国应用生理学杂志, 2022, 38(5): 569-576.
[10]	陈懿婷, 褚智恒, 傅瑾雯 ,陶嘉颖, 陈佳玉. 大黄酸诱导胃癌细胞HGC-27凋亡的作用及其机制^*[J]. 中国应用生理学杂志, 2022, 38(5): 584-589.
[11]	刘凯, 孙新迪, 张伟伟, 杨清竹, 黄鑫, 邵淑丽. 利用CRISPRi下调 MDR1基因表达增强肺腺癌 A549/DDP细胞对顺铂敏感性^*[J]. 中国应用生理学杂志, 2022, 38(5): 590-594.
[12]	张晓东, 孙石磊, 王冠, 李霄凌, 姚立杰, 徐浩, 张鹏, 沈雷. 雌激素处理的hBMSC对高糖诱导血管内皮细胞损伤的保护作用^*[J]. 中国应用生理学杂志, 2022, 38(4): 289-294.
[13]	孟茜, 张瑾, 陈奎妃, 陈弘, 杨林军, 陈佳玉. 亚硒酸钠对弥漫性大B细胞淋巴瘤SU-DHL-4细胞的干预作用及其机制^*[J]. 中国应用生理学杂志, 2022, 38(4): 313-316.
[14]	谷城威, 钱河, 刘玉珍, 赵宝生. TOFA对人食管鳞癌Eca109和KYSE-450细胞生长的影响^*[J]. 中国应用生理学杂志, 2022, 38(4): 317-321.
[15]	孟令雪, 孙新迪, 张伟伟, 郭旭, 沈洋, 邵淑丽. 利用CRISPRi技术沉默MRP1基因增强A549/DDP细胞对顺铂的敏感性^*[J]. 中国应用生理学杂志, 2022, 38(4): 322-325.